Ying Cui | Immunology and Microbiology | Excellence in Research Award

Published on by Forensic Scientist

Ms. Ying Cui | Immunology and Microbiology | Excellence in Research Award

Beijing Friendship Hospital, Capital Medical University | China

Ms. Ying Cui is an emerging neuroscientist whose research advances the understanding of the gut–brain axis, neurodegeneration mechanisms, and biomarker innovation in Parkinson’s disease (PD). Her work integrates metagenomics, multi-parameter clinical imaging, molecular neuroscience, and machine-learning analytics to improve diagnostic precision and support translational therapeutic development. With 6 Scopus-indexed publications, 85 citations, and an h-index of 2, her research impact continues to grow across both clinical and experimental domains. Ms. Ying Cui has contributed to high-value research projects, including multicenter clinical trials and national-level neuroscience studies, where she played key roles in microbiome profiling, experimental methodology, and advanced neuroimaging assessment using ¹²³I-MIBG scintigraphy. Her first-author publications provide novel insights into the diagnostic performance of cardiac and extra-cardiac washout rate parameters for differentiating PD from Parkinson-plus syndromes, offering clinically relevant imaging markers for complex diagnostic scenarios. Complementing her imaging research, Ying has developed a high-accuracy metagenomic diagnostic model with 99% validation accuracy and identified functional probiotic strains with the potential to modulate α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammatory signaling work that has led to a PCT international patent for a probiotic composition targeting REM Sleep Behavior Disorder. Her multidisciplinary contributions span biomarker discovery, clinical–computational integration, translational microbiome innovation, and cross-institutional collaborations in neurology, microbiology, metabolomics, and bioinformatics. Through this synergistic research portfolio, Ying Cui continues to advance early diagnostic strategies, mechanistic insights, and therapeutic innovation in Parkinson’s disease, establishing herself as a rising researcher in translational neurodegeneration science.

Profiles: Scopus | ORCID

Featured Publications

  • Xue, T., Cui, Y., Kan, Y., & Yang, J. (2025). Value of extra-cardiac sympathetic nervous uptake parameters based on ¹²³I-MIBG SPECT/CT in the assessment of Parkinson’s disease. Clinical and Translational Imaging.

  • Xue, T., Cui, Y., Kan, Y., & Yang, J. (2025). Value of multi-parameter ¹²³I-MIBG scintigraphy in the differential diagnosis of Parkinson’s disease. EJNMMI Research.

Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Guilan University of Medical Sciences | Iran

Dr. Majid Taati Moghadam is a dedicated Medical Microbiologist and Antimicrobial Resistance Researcher based in Rasht, Iran. He specializes in microbial pathogenesis, antibiotic resistance mechanisms, bacteriophage therapy, and the connection between microbiota and neurodegenerative disorders. His multidisciplinary expertise extends across clinical microbiology, infectious disease prevention, and translational therapeutics, making him a leading figure in Iran’s microbiological research community.

Professional Profile

Scopus

Google Scholar

ORCID

Education

Dr. Majid Taati holds a Ph.D. in Medical Bacteriology from Iran University of Medical Sciences (2017–2022), where his research investigated the relationship between oral microbiome shifts and Alzheimer’s disease. He earned his Master’s degree in Medical Microbiology from Kerman University of Medical Sciences (2012–2015), focusing on carbapenem resistance genes in Klebsiella pneumoniae. His academic journey began with a Bachelor’s degree in Microbiology from Islamic Azad University, Lahijan Branch (2007–2012). Throughout his studies, he demonstrated a keen interest in antibiotic resistance, clinical diagnostics, and the molecular biology of pathogens.

Experience

Dr. Majid Taati has played key roles in over a dozen microbiological research projects across Iran. As both a principal investigator and main collaborator, he has contributed to studies on extended-spectrum beta-lactamase (ESBL) genes, resistance enzymes in E. coli, and the antimicrobial effects of plant extracts like Ephedra pachyclada. He has worked extensively on projects involving nosocomial infections, multidrug-resistant bacteria, and genetic analysis methods such as MLVA and HRM techniques. He also authored the textbook Essential Medical Microbiology in Persian, and presented his findings at several major Iranian congresses, including the International Microbiology Congress. His laboratory and academic experience bridges both applied research and educational leadership.

Research Interests

Dr. Majid Taati research focuses on antimicrobial resistance mechanisms, phage and endolysin therapy, bacterial biofilm inhibition, and engineered phage enzymes for resistant infections. He is also deeply involved in exploring the role of microbiota in neurological and neuropsychiatric disorders, especially Alzheimer’s disease. His studies aim to bridge clinical microbiology with therapeutic innovation addressing global health threats posed by superbugs like carbapenem- and colistin-resistant Gram-negative bacteria. His recent projects extend to wound healing biomaterials, phage protein therapies, and microbiome-based diagnostics, reflecting his broad and multidisciplinary scientific interests.

Awards

Recognized for his extensive research contributions, Dr. Majid Taati is a deserving nominee for the “Best Researcher Award” in medical microbiology and antimicrobial resistance. His scholarly excellence, particularly in phage therapy and resistance gene profiling, aligns well with the objectives of scientific bodies that honor groundbreaking research. With dozens of publications in top-tier journals and continuous involvement in nationally significant projects, he exemplifies leadership in translational microbiology and global infectious disease research.

Publications

  • Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
    Year: 2020
    Citations: 316

  • Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
    Year: 2020
    Citations: 311

  • How phages overcome the challenges of drug resistant bacteria in clinical infections
    Year: 2020
    Citations: 173

  • Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials
    Year: 2020
    Citations: 125

  • COVID-19 (Coronavirus disease 2019): a new coronavirus disease
    Year: 2020
    Citations: 108

  • Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples
    Year: 2019
    Citations: 108

  • Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria
    Year: 2021
    Citations: 58

Conclusion

Dr. Majid Taati Moghaddam Ziabari has built an impressive career defined by scientific innovation, deep academic rigor, and a commitment to combating infectious diseases. His pioneering work in bacteriophage therapy and antimicrobial resistance not only advances microbiological science but also addresses some of the most urgent global health challenges. With his rich publication record, research leadership, and academic influence, he is a prime candidate for international recognition, especially the Best Researcher Award. His career serves as a model of excellence in translational research and academic impact.